Director Dealing

Physiomics PLC
25 July 2023
 

25 July 2023

 

Physiomics plc

("PYC" or the "Company")

 

Director Dealing

 

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Millen.

 

Accordingly, Dr Millen's total holding in the Company will remain unchanged at 1,884,393 Ordinary Shares, representing approximately 1.39 per cent. of the Company's issued share capital.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO                                                                                                           +44 (0)1865 784 980

 

Hybridan LLP (Broker)                                                                                                   +44 (0) 203 764 2341

Claire Louise Noyce

 

Strand Hanson Ltd (NOMAD)                                                                                         +44 (0)20 7409 3494

James Dance

James Bellman

 

 

 

 

The Company's LEI is 213800A71DSZ6ABMTQ91

 

 

PDMR Notification Forms

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

James Millen

2.

Reason for the Notification

a)

Position/status

Executive Chairman and CEO

b)

Initial notification/amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4.

Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Physiomics plc Ordinary Shares

Identification code

ISIN:  GB00BDR6W943

b)

Nature of the Transaction

Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited.

c)

Price(s) and volume(s)

Dr Jim Millen

Price(s)

Volume(s)

N/A

500,000

d)

Aggregated information

-       Aggregated volume

 

-       Price

 

 

500,000

N/A

e)

Date of the transaction

22 July 2023

f)

Place of the transaction

Off market transaction

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Physiomics (PYC)
UK 100

Latest directors dealings